{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:34:12Z","timestamp":1792679652948,"version":"4.5.0"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":645,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1038\/mto.2015.11","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T17:40:58Z","timestamp":1437500458000},"page":"15011","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency"],"prefix":"10.1016","volume":"2","author":[{"given":"Olga V","family":"Matveeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong S","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana A","family":"Shabalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M","family":"Chumakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mto.2015.11_bib1","series-title":"Fields Virology, 5th edn","first-page":"1449","author":"Lamb","year":"2007"},{"key":"10.1038\/mto.2015.11_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10719-006-5433-0","article-title":"Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview","volume":"23","author":"Villar","year":"2006","journal-title":"Glycoconj J"},{"issue":"Pt 2","key":"10.1038\/mto.2015.11_bib3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1099\/vir.0.82150-0","article-title":"Newcastle disease virus may enter cells by caveolae-mediated endocytosis","volume":"88","author":"Cant\u00edn","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1038\/mto.2015.11_bib4","first-page":"6396","article-title":"Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy","volume":"60","author":"Higuchi","year":"2000","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-4614-7651-1_6","article-title":"Paramyxovirus entry","volume":"790","author":"Bossart","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"10.1038\/mto.2015.11_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/128_2013_466","article-title":"Sialic acid receptors of viruses","author":"Matrosovich","year":"2013","journal-title":"Top Curr Chem"},{"key":"10.1038\/mto.2015.11_bib7","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1158\/0008-5472.CAN-14-0728","article-title":"Sialic acids sweeten a tumor's life","volume":"74","author":"B\u00fcll","year":"2014","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib8","first-page":"238","article-title":"Sweet escape: sialic acids in tumor immune evasion","volume":"1846","author":"B\u00fcll","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/mto.2015.11_bib9","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/ijc.24234","article-title":"Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle","volume":"124","author":"Kawaguchi","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1038\/mto.2015.11_bib10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.cgt.7700823","article-title":"Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer","volume":"12","author":"Myers","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mto.2015.11_bib11","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","article-title":"High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus","volume":"64","author":"Anderson","year":"2004","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib12","doi-asserted-by":"crossref","first-page":"e1002240","DOI":"10.1371\/journal.ppat.1002240","article-title":"Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus","volume":"7","author":"Noyce","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1038\/mto.2015.11_bib13","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","article-title":"Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer","volume":"69","author":"Takano","year":"2009","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1309\/AJCPGXK0FR4MHIHB","article-title":"Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker","volume":"134","author":"Derycke","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/mto.2015.11_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2407-7-73","article-title":"Nectin-4 is a new histological and serological tumor associated marker for breast cancer","volume":"7","author":"Fabre-Lafay","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1038\/mto.2015.11_bib16","doi-asserted-by":"crossref","first-page":"e1000973","DOI":"10.1371\/journal.ppat.1000973","article-title":"Paramyxovirus entry and targeted vectors for cancer therapy","volume":"6","author":"Cattaneo","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1038\/mto.2015.11_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1927","article-title":"Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded","volume":"6","author":"Cattaneo","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"10.1038\/mto.2015.11_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mto.2015.11_bib19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2174\/187152012802650237","article-title":"RECKing MMP: relevance of reversion-inducing cysteine-rich protein with kazal motifs as a prognostic marker and therapeutic target for cancer (a review)","volume":"12","author":"Nagini","year":"2012","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1038\/mto.2015.11_bib20","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s13277-013-0842-8","article-title":"Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets","volume":"34","author":"Hadler-Olsen","year":"2013","journal-title":"Tumour Biol"},{"key":"10.1038\/mto.2015.11_bib21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/sj.gt.3302272","article-title":"Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases","volume":"11","author":"Kinoh","year":"2004","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.11_bib22","doi-asserted-by":"crossref","first-page":"7694","DOI":"10.1158\/0008-5472.CAN-06-0538","article-title":"Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases","volume":"66","author":"Springfeld","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib23","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.1158\/0008-5472.CAN-09-4650","article-title":"Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus","volume":"70","author":"M\u00fchlebach","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib24","first-page":"95","article-title":"The genes of interferons and interferon-related factors: localization and relationships with chromosome aberrations in cancer","volume":"48","author":"Haus","year":"2000","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1038\/mto.2015.11_bib25","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1128\/JVI.01537-10","article-title":"Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells","volume":"85","author":"Mansour","year":"2011","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.11_bib26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/clpt.2010.211","article-title":"Therapeutic potential of oncolytic measles virus: promises and challenges","volume":"88","author":"Galanis","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/mto.2015.11_bib27","first-page":"6566","article-title":"Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells","volume":"62","author":"Bateman","year":"2002","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/cgt.2009.74","article-title":"Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer","volume":"17","author":"Lin","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mto.2015.11_bib29","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1158\/0008-5472.CAN-03-3753","article-title":"Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer","volume":"64","author":"Ebert","year":"2004","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib30","first-page":"2727","article-title":"Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms","volume":"9","author":"Nakamori","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.11_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/mt.2009.231","article-title":"Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma","volume":"18","author":"Altomonte","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.11_bib32","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1128\/JVI.01054-08","article-title":"A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P\/V mutant without compromising sensitivity to type I interferon","volume":"82","author":"Gainey","year":"2008","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.11_bib33","first-page":"1492","article-title":"Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth","volume":"60","author":"Bateman","year":"2000","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1089\/104303401750148766","article-title":"Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas","volume":"12","author":"Galanis","year":"2001","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mto.2015.11_bib35","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/jgm.616","article-title":"Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas","volume":"6","author":"Allen","year":"2004","journal-title":"J Gene Med"},{"key":"10.1038\/mto.2015.11_bib36","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.3748\/wjg.v13.i22.3063","article-title":"In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines","volume":"13","author":"Hoffmann","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1038\/mto.2015.11_bib37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/hum.2006.185","article-title":"Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis","volume":"18","author":"Hoffmann","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mto.2015.11_bib38","first-page":"85","article-title":"Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis","volume":"21","author":"Washburn","year":"2002","journal-title":"Int J Oncol"},{"key":"10.1038\/mto.2015.11_bib39","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1038\/mto.2015.11_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mto.2015.11_bib41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0952-7915(00)00191-6","article-title":"Danger signals: SOS to the immune system","volume":"13","author":"Gallucci","year":"2001","journal-title":"Curr Opin Immunol"},{"key":"10.1038\/mto.2015.11_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08830185.2010.529976","article-title":"Pathogen recognition by the innate immune system","volume":"30","author":"Kumar","year":"2011","journal-title":"Int Rev Immunol"},{"key":"10.1038\/mto.2015.11_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-065X.2012.01146.x","article-title":"PAMPs and DAMPs: signal 0s that spur autophagy and immunity","volume":"249","author":"Tang","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1038\/mto.2015.11_bib44","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front Oncol"},{"key":"10.1038\/mto.2015.11_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression","volume":"22","author":"Ostrand-Rosenberg","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"10.1038\/mto.2015.11_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1038\/mto.2015.11_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/cdd.2013.84","article-title":"Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments","volume":"21","author":"Inoue","year":"2014","journal-title":"Cell Death Differ"},{"key":"10.1038\/mto.2015.11_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/202303b0","article-title":"Quantitative relationships in viral oncolysis and the possibility of artificial heterogenization of tumours","volume":"202","author":"Svet-Moldavsky","year":"1964","journal-title":"Nature"},{"key":"10.1038\/mto.2015.11_bib49","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4049\/jimmunol.117.4.1250","article-title":"Xenogenization of rat erythroid cells by lymphatic leukemia virus: its role in induction of autoimmune hemolytic anemia","volume":"117","author":"Kuzumaki","year":"1976","journal-title":"J Immunol"},{"key":"10.1038\/mto.2015.11_bib50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/gt.2011.205","article-title":"Measles virus causes immunogenic cell death in human melanoma","volume":"20","author":"Donnelly","year":"2013","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.11_bib51","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","article-title":"Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response","volume":"68","author":"Gauvrit","year":"2008","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib52","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/biology2020587","article-title":"Antitumor virotherapy by attenuated measles virus","volume":"2","author":"Guillerme","year":"2013","journal-title":"Biology"},{"key":"10.1038\/mto.2015.11_bib53","doi-asserted-by":"crossref","first-page":"43651","DOI":"10.1074\/jbc.M112.399964","article-title":"RNase L induces autophagy via c-Jun N-terminal kinase and double-stranded RNA-dependent protein kinase signaling pathways","volume":"287","author":"Siddiqui","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1038\/mto.2015.11_bib54","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1056\/NEJMra1205406","article-title":"Autophagy in human health and disease","volume":"368","author":"Choi","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/mto.2015.11_bib55","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2161","article-title":"Unveiling the roles of autophagy in innate and adaptive immunity","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1038\/mto.2015.11_bib56","doi-asserted-by":"crossref","first-page":"e1003599","DOI":"10.1371\/journal.ppat.1003599","article-title":"Sustained autophagy contributes to measles virus infectivity","volume":"9","author":"Richetta","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1038\/mto.2015.11_bib57","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00705-012-1248-4","article-title":"Whole genome sequencing and biological characterization of Duck\/JS\/10, a new lentogenic class I Newcastle disease virus","volume":"157","author":"Meng","year":"2012","journal-title":"Arch Virol"},{"key":"10.1038\/mto.2015.11_bib58","doi-asserted-by":"crossref","first-page":"8527","DOI":"10.1128\/JVI.00807-12","article-title":"Membrane fusion-mediated autophagy induction enhances morbillivirus cell-to-cell spread","volume":"86","author":"Delpeut","year":"2012","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.11_bib59","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.chom.2009.09.006","article-title":"Autophagy induction by the pathogen receptor CD46","volume":"6","author":"Joubert","year":"2009","journal-title":"Cell Host Microbe"},{"key":"10.1038\/mto.2015.11_bib60","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1128\/JVI.77.2.1501-1511.2003","article-title":"Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins","volume":"77","author":"Park","year":"2003","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.11_bib61","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1348-0421.2001.tb01315.x","article-title":"Paramyxovirus accessory proteins as interferon antagonists","volume":"45","author":"Gotoh","year":"2001","journal-title":"Microbiol Immunol"},{"key":"10.1038\/mto.2015.11_bib62","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1128\/JVI.06405-11","article-title":"Paramyxovirus V proteins interact with the RNA Helicase LGP2 to inhibit RIG-I-dependent interferon induction","volume":"86","author":"Childs","year":"2012","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.11_bib63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-5793(03)00528-3","article-title":"Measles virus V protein blocks interferon (IFN)-alpha\/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation","volume":"545","author":"Takeuchi","year":"2003","journal-title":"FEBS Lett"},{"key":"10.1038\/mto.2015.11_bib64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.virol.2011.12.011","article-title":"The nucleocapsid protein of measles virus blocks host interferon response","volume":"424","author":"Takayama","year":"2012","journal-title":"Virology"},{"key":"10.1038\/mto.2015.11_bib65","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0042-6822(03)00537-3","article-title":"The C protein of measles virus inhibits the type I interferon response","volume":"315","author":"Shaffer","year":"2003","journal-title":"Virology"},{"key":"10.1038\/mto.2015.11_bib66","doi-asserted-by":"crossref","first-page":"e90508","DOI":"10.1371\/journal.pone.0090508","article-title":"Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors","volume":"9","author":"Zimmermann","year":"2014","journal-title":"PLoS ONE"},{"issue":"Pt A","key":"10.1038\/mto.2015.11_bib67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0076-6879(81)78094-7","article-title":"Production of interferon in human leukocytes from normal donors with the use of Sendai virus","volume":"78","author":"Cantell","year":"1981","journal-title":"Meth Enzymol"},{"key":"10.1038\/mto.2015.11_bib68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jlb.60.1.125","article-title":"Cytokines induced by Sendai virus in human peripheral blood leukocytes","volume":"60","author":"Hua","year":"1996","journal-title":"J Leukoc Biol"},{"issue":"Pt 2","key":"10.1038\/mto.2015.11_bib69","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1042\/bj3290295","article-title":"Identification of nine interferon-alpha subtypes produced by Sendai virus-induced human peripheral blood leucocytes","volume":"329","author":"Nyman","year":"1998","journal-title":"Biochem J"},{"key":"10.1038\/mto.2015.11_bib70","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/jir.1993.13.407","article-title":"Superinduction of mitogen-stimulated interferon-gamma production and other lymphokines by Sendai virus","volume":"13","author":"Costas","year":"1993","journal-title":"J Interferon Res"},{"key":"10.1038\/mto.2015.11_bib71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/viro.2002.1413","article-title":"Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus","volume":"297","author":"Zeng","year":"2002","journal-title":"Virology"},{"key":"10.1038\/mto.2015.11_bib72","first-page":"673","article-title":"Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA","volume":"23","author":"Fournier","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1038\/mto.2015.11_bib73","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-1-59745-561-9_30","article-title":"Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer","volume":"542","author":"Schirrmacher","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1038\/mto.2015.11_bib74","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/jir.2010.0158","article-title":"Interferon: current status and future prospects in cancer therapy","volume":"31","author":"Wang","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"10.1038\/mto.2015.11_bib75","first-page":"3301","article-title":"Maturation of tumor vasculature by interferon-beta disrupts the vascular niche of glioma stem cells","volume":"30","author":"Williams","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1038\/mto.2015.11_bib76","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1038\/mto.2015.11_bib77","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","article-title":"The two faces of interferon-\u03b3 in cancer","volume":"17","author":"Zaidi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.11_bib78","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jir.2012.0167","article-title":"Immunomodulatory effects of interferons in malignancies","volume":"33","author":"Bekisz","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"10.1038\/mto.2015.11_bib79","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-230X(08)00407-7","article-title":"IFN inducibility of major histocompatibility antigens in tumors","volume":"101","author":"Seliger","year":"2008","journal-title":"Adv Cancer Res"},{"key":"10.1038\/mto.2015.11_bib80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1359-6101(01)00038-7","article-title":"The roles of IFN gamma in protection against tumor development and cancer immunoediting","volume":"13","author":"Ikeda","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1038\/mto.2015.11_bib81","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni1213","article-title":"A critical function for type I interferons in cancer immunoediting","volume":"6","author":"Dunn","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1038\/mto.2015.11_bib82","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/1078-0432.CCR-12-1947","article-title":"Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN-\u03b3 production","volume":"19","author":"Saga","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.11_bib83","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-06-1615","article-title":"Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells","volume":"67","author":"Kurooka","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib84","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.febslet.2008.03.011","article-title":"Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner","volume":"582","author":"Suzuki","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1038\/mto.2015.11_bib85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00262-007-0351-y","article-title":"Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation","volume":"57","author":"Fujihara","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1038\/mto.2015.11_bib86","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.4049\/jimmunol.168.7.3195","article-title":"IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking","volume":"168","author":"Dufour","year":"2002","journal-title":"J Immunol"},{"key":"10.1038\/mto.2015.11_bib87","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mto.2015.11_bib88","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/jnci\/80.16.1305","article-title":"Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity","volume":"80","author":"Lorence","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mto.2015.11_bib89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/cbr.1994.9.225","article-title":"Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus","volume":"9","author":"Zorn","year":"1994","journal-title":"Cancer Biother"},{"key":"10.1038\/mto.2015.11_bib90","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.4049\/jimmunol.170.4.1814","article-title":"TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus","volume":"170","author":"Washburn","year":"2003","journal-title":"J Immunol"},{"key":"10.1038\/mto.2015.11_bib91","first-page":"363","article-title":"Newcastle disease virus activates macrophages for anti-tumor activity","volume":"16","author":"Schirrmacher","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1038\/mto.2015.11_bib92","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"10.1038\/mto.2015.11_bib93","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1128\/JVI.00211-09","article-title":"Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase","volume":"83","author":"Jarahian","year":"2009","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.11_bib94","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A","article-title":"Recognition of viral hemagglutinins by NKp44 but not by NKp30","volume":"31","author":"Arnon","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1038\/mto.2015.11_bib95","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/35059110","article-title":"Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells","volume":"409","author":"Mandelboim","year":"2001","journal-title":"Nature"},{"key":"10.1038\/mto.2015.11_bib96","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood-2003-05-1716","article-title":"The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46","volume":"103","author":"Arnon","year":"2004","journal-title":"Blood"},{"key":"10.1038\/mto.2015.11_bib97","doi-asserted-by":"crossref","first-page":"874","DOI":"10.4161\/onci.20636","article-title":"Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk","volume":"1","author":"Chinnery","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1038\/mto.2015.11_bib98","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.2741\/3850","article-title":"Dramatic improvement of DC-based immunotherapy against various malignancies","volume":"16","author":"Harada","year":"2011","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1038\/mto.2015.11_bib99","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.4049\/jimmunol.0901641","article-title":"Provision of continuous maturation signaling to dendritic cells by RIG-I-stimulating cytosolic RNA synthesis of Sendai virus","volume":"186","author":"Okano","year":"2011","journal-title":"J Immunol"},{"key":"10.1038\/mto.2015.11_bib100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1535-7163.MCT-10-0479","article-title":"Antagonism of VEGF by genetically engineered dendritic cells is essential to induce antitumor immunity against malignant ascites","volume":"10","author":"Sugiyama","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/mto.2015.11_bib101","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbrc.2007.01.132","article-title":"Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells","volume":"355","author":"Yoneyama","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mto.2015.11_bib102","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.2741\/2809","article-title":"Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen","volume":"13","author":"Yonemitsu","year":"2008","journal-title":"Front Biosci"},{"key":"10.1038\/mto.2015.11_bib103","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.4049\/jimmunol.0803845","article-title":"Sustained and NK\/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus","volume":"183","author":"Komaru","year":"2009","journal-title":"J Immunol"},{"key":"10.1038\/mto.2015.11_bib104","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1593\/neo.10732","article-title":"RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer","volume":"12","author":"Kato","year":"2010","journal-title":"Neoplasia"},{"key":"10.1038\/mto.2015.11_bib105","first-page":"1135","article-title":"Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection","volume":"3","author":"Schirrmacher","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.11_bib106","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1073\/pnas.77.7.4336","article-title":"Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line","volume":"77","author":"Pearlstein","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mto.2015.11_bib107","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1126\/science.7233237","article-title":"Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines","volume":"212","author":"Yogeeswaran","year":"1981","journal-title":"Science"},{"key":"10.1038\/mto.2015.11_bib108","first-page":"376","article-title":"Sialic acid as a tumor marker","volume":"24","author":"Narayanan","year":"1994","journal-title":"Ann Clin Lab Sci"},{"key":"10.1038\/mto.2015.11_bib109","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00000478-199404000-00008","article-title":"Polysialic acid of the neural cell adhesion molecule in the human thyroid: a marker for medullary thyroid carcinoma and primary C-cell hyperplasia. An immunohistochemical study on 79 thyroid lesions","volume":"18","author":"Komminoth","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/mto.2015.11_bib110","first-page":"1435","article-title":"Expression of alpha 2,6-linked sialic acid residues in neoplastic but not in normal human colonic mucosa. A lectin-gold cytochemical study with Sambucus nigra and Maackia amurensis lectins","volume":"139","author":"Sata","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1038\/mto.2015.11_bib111","first-page":"4249","article-title":"Increased alpha2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma","volume":"57","author":"Pousset","year":"1997","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib112","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000030122","article-title":"Immunohistochemical analysis of sialic acid and fucose composition in human colorectal adenocarcinoma","volume":"21","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2000","journal-title":"Tumour Biol"},{"key":"10.1038\/mto.2015.11_bib113","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3797\/scipharm.1205-01","article-title":"Development of antimetastatic drugs by targeting tumor sialic acids","volume":"80","author":"Lu","year":"2012","journal-title":"Sci Pharm"},{"key":"10.1038\/mto.2015.11_bib114","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00193501","article-title":"Native and sialic acid masked Lewis(a) antigen reactivity in medullary thyroid carcinoma. Distinct tumour-associated and prognostic relevant antigens","volume":"424","author":"Vierbuchen","year":"1994","journal-title":"Virchows Arch"},{"key":"10.1038\/mto.2015.11_bib115","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.4049\/jimmunol.1001635","article-title":"Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting","volume":"185","author":"Cohen","year":"2010","journal-title":"J Immunol"},{"key":"10.1038\/mto.2015.11_bib116","series-title":"The Paramyxoviruses","author":"Kingsbury","year":"1991"},{"key":"10.1038\/mto.2015.11_bib117","series-title":"Paramyxoviruses","author":"Enders","year":"1996"},{"key":"10.1038\/mto.2015.11_bib118","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4049\/jimmunol.139.1.262","article-title":"Cell surface sialic acid influences tumor cell recognition in the mixed lymphocyte reaction","volume":"139","author":"Powell","year":"1987","journal-title":"J Immunol"},{"key":"10.1038\/mto.2015.11_bib119","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrmicro3140","article-title":"New viruses for cancer therapy: meeting clinical needs","volume":"12","author":"Miest","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1038\/mto.2015.11_bib120","first-page":"233","article-title":"Oncolytic effect of poliomyelitis virus on human epidermoid carcinoma (hela tumor) heterologously transplanted to guinea pigs","volume":"45","author":"Pond","year":"1964","journal-title":"Am J Pathol"},{"key":"10.1038\/mto.2015.11_bib121","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/1097-0142(197610)38:4<1796::AID-CNCR2820380457>3.0.CO;2-Y","article-title":"The morphology of tumors of the human gastrointestinal tract in short-term organ culture and the reaction of these tumors to infection with poliovirus","volume":"38","author":"Tsypkin","year":"1976","journal-title":"Cancer"},{"key":"10.1038\/mto.2015.11_bib122","first-page":"81","article-title":"Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo","volume":"38","author":"Toyoda","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1038\/mto.2015.11_bib123","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1134\/S0026893312050032","article-title":"[Oncolytic enteroviruses]","volume":"46","author":"Chumakov","year":"2012","journal-title":"Mol Biol (Mosk)"},{"key":"10.1038\/mto.2015.11_bib124","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/1471-2407-12-368","article-title":"Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway","volume":"12","author":"Twigger","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1038\/mto.2015.11_bib125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cytogfr.2010.02.011","article-title":"Oncolytic parvoviruses as cancer therapeutics","volume":"21","author":"Rommelaere","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1038\/mto.2015.11_bib126","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1357-4310(97)81456-6","article-title":"Replicating viruses as selective cancer therapeutics","volume":"2","author":"Kirn","year":"1996","journal-title":"Mol Med Today"},{"key":"10.1038\/mto.2015.11_bib127","first-page":"556","article-title":"[Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives]","volume":"46","author":"Sviatchenko","year":"2012","journal-title":"Mol Biol (Mosk)"},{"key":"10.1038\/mto.2015.11_bib128","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/mto.2015.11_bib129","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1089\/vim.2004.17.516","article-title":"Vesicular stomatitis virus as an oncolytic vector","volume":"17","author":"Barber","year":"2004","journal-title":"Viral Immunol"},{"key":"10.1038\/mto.2015.11_bib130","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1517\/14712598.4.10.1685","article-title":"Oncolytic measles viruses for cancer therapy","volume":"4","author":"Nakamura","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1038\/mto.2015.11_bib131","author":"Kirn","year":"2008","journal-title":"Oncolytic vaccinia virus cancer therapy"},{"key":"10.1038\/mto.2015.11_bib132","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3103\/S0891416812010041","article-title":"Oncolytic poxviruses","volume":"27","author":"Kochneva","year":"2012","journal-title":"Mol Genet Microbiol Virol"},{"key":"10.1038\/mto.2015.11_bib133","first-page":"431","article-title":"Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein","volume":"26","author":"Bian","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1038\/mto.2015.11_bib134","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-61779-340-0_11","article-title":"Oncolytic measles virus retargeting by ligand display","volume":"797","author":"Msaouel","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1038\/mto.2015.11_bib135","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1128\/JVI.69.6.3341-3349.1995","article-title":"Functional and structural interactions between measles virus hemagglutinin and CD46","volume":"69","author":"Nussbaum","year":"1995","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.11_bib136","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1158\/0008-5472.CAN-06-1200","article-title":"Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity","volume":"66","author":"Allen","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib137","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nbt1060","article-title":"Rescue and propagation of fully retargeted oncolytic measles viruses","volume":"23","author":"Nakamura","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mto.2015.11_bib138","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.mt.6300105","article-title":"Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas","volume":"15","author":"Paraskevakou","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.11_bib139","doi-asserted-by":"crossref","first-page":"13149","DOI":"10.1128\/JVI.01415-07","article-title":"Affinity thresholds for membrane fusion triggering by viral glycoproteins","volume":"81","author":"Hasegawa","year":"2007","journal-title":"J Virol"},{"issue":"20 Pt 1","key":"10.1038\/mto.2015.11_bib140","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1158\/1078-0432.CCR-06-0992","article-title":"The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer","volume":"12","author":"Hasegawa","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mto.2015.11_bib141","doi-asserted-by":"crossref","first-page":"10939","DOI":"10.1158\/0008-5472.CAN-07-1252","article-title":"Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine","volume":"67","author":"Ungerechts","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib142","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1158\/0008-5472.CAN-04-2879","article-title":"Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression","volume":"65","author":"Hallak","year":"2005","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib143","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/mt.2008.152","article-title":"Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity","volume":"16","author":"Allen","year":"2008","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.11_bib144","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.11_bib145","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1297-9716-42-122","article-title":"Virulence of Newcastle disease virus: what is known so far?","volume":"42","author":"Dortmans","year":"2011","journal-title":"Vet Res"},{"key":"10.1038\/mto.2015.11_bib146","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/fmb.12.4","article-title":"Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions","volume":"7","author":"Zamarin","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1038\/mto.2015.11_bib147","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1158\/0008-5472.CAN-07-1025","article-title":"Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus","volume":"67","author":"Vigil","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mto.2015.11_bib148","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/mt.2008.286","article-title":"Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses","volume":"17","author":"Zamarin","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mto.2015.11_bib149","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/gt.2009.14","article-title":"Genetically engineered Newcastle disease virus for malignant melanoma therapy","volume":"16","author":"Zamarin","year":"2009","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.11_bib150","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00109-010-0605-6","article-title":"Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer","volume":"88","author":"Song","year":"2010","journal-title":"J Mol Med"},{"key":"10.1038\/mto.2015.11_bib151","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1158\/1535-7163.MCT-10-0090","article-title":"Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma","volume":"9","author":"Silberhumer","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/mto.2015.11_bib152","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hed.21609","article-title":"Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer","volume":"33","author":"Li","year":"2011","journal-title":"Head Neck"},{"key":"10.1038\/mto.2015.11_bib153","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1128\/JVI.00241-06","article-title":"Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death","volume":"80","author":"Elankumaran","year":"2006","journal-title":"J Virol"},{"key":"10.1038\/mto.2015.11_bib154","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2741\/2847","article-title":"New cancer therapy using genetically-engineered oncolytic Sendai virus vector","volume":"13","author":"Kinoh","year":"2008","journal-title":"Front Biosci"},{"key":"10.1038\/mto.2015.11_bib155","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/gt.2008.167","article-title":"Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies","volume":"16","author":"Kinoh","year":"2009","journal-title":"Gene Ther"},{"key":"10.1038\/mto.2015.11_bib156","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"6C","key":"10.1038\/mto.2015.11_bib157","first-page":"4943","article-title":"CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients","volume":"26","author":"Surowiak","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1038\/mto.2015.11_bib158","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/PAI.0b013e31821a0be9","article-title":"CD46 Expression is an unfavorable prognostic factor in breast cancer cases","volume":"19","author":"Maciejczyk","year":"2011","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/mto.2015.11_bib159","first-page":"19","article-title":"Nectin 4 is the epithelial cell receptor for measles virus","volume":"19","author":"Noyce","year":"2012","journal-title":"Trends Microbiol"},{"key":"10.1038\/mto.2015.11_bib160","doi-asserted-by":"crossref","first-page":"19543","DOI":"10.1074\/jbc.M410943200","article-title":"Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)\/ADAM-17","volume":"280","author":"Fabre-Lafay","year":"2005","journal-title":"J Biol Chem"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770516300134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T07:20:43Z","timestamp":1691824843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770516300134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":160,"alternative-id":["S2372770516300134"],"URL":"https:\/\/doi.org\/10.1038\/mto.2015.11","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]},"article-number":"15011"}}